Researchers at the Francis Crick Institute have identified a previously underappreciated link between the nervous system and lung cancer, showing that sensory nerve signals can help tumors evade the immune system. The study, published in Cell, suggests that nerves in the tumor microenvironment are not passive bystanders. Instead, they can actively shape whether immune cells organize effectively enough to mount a strong anti-cancer response.
A new neuroimmune mechanism in lung cancer
The work focused on sensory nerves that normally act as part of the body’s early warning system, detecting extreme thermal, physical, or chemical threats and triggering protective responses. In mouse models, the researchers activated and deactivated these nerves and found that their presence in the tumor microenvironment was supporting tumor growth rather than limiting it.
The team also found that lung tumors can increase the growth and activity of these nerves. That process triggers the release of calcitonin gene-related peptide, or CGRP, a chemical messenger already familiar in other areas of medicine. Using cell and mouse models, the researchers showed that CGRP interacts with macrophages in ways that interfere with the formation of tertiary lymphoid structures, clusters of immune cells associated with better outcomes in people with lung cancer.
Those structures matter because the strength of an immune response depends on more than whether immune cells are present. It also depends on how those cells are organized within the tumor microenvironment. By preventing that organization from taking shape, the nerve-driven signal appears to blunt the immune system’s ability to fight back.
What happened when the pathway was blocked
When researchers disrupted local sensory nerve activity, or directly blocked CGRP signaling, the effect reversed. Tertiary lymphoid structures increased, immune responses became stronger, and tumor growth fell. That combination is what makes the finding notable: it ties a specific nerve signal to a structural change in the tumor environment and to a measurable change in tumor behavior.
The study also found that cigarette smoke can further exploit this interaction, accelerating tumor growth in mice. That detail adds another layer to a well-established lung cancer risk factor. It suggests smoke exposure may not only contribute to cancer development but may also help tumors manipulate local biology in ways that weaken immune defense.
Why the finding matters now
The translational appeal is clear. Drugs that target CGRP signaling already exist for other conditions, including migraine. That does not mean they are ready to be repurposed immediately for lung cancer, but it does mean researchers are not starting from scratch if future studies support the approach in people.
For cancer research, the study adds to a broader shift in thinking about tumors as ecosystems rather than isolated masses of malignant cells. Immune cells, connective tissue, signaling molecules, blood vessels, and now nerves are increasingly understood as participants in whether disease progresses or responds to treatment. The Crick team’s findings place sensory nerves directly inside that conversation.
It also arrives at a time when immunotherapy remains transformative for some lung cancer patients but uneven in its benefits. A major challenge is understanding why some tumors remain resistant even when immune cells are present. This study offers one possible explanation: the local nerve network may be helping create conditions that suppress useful immune organization.
The immediate next step will be determining how far these findings extend beyond the mouse and cell systems used in the study, and whether the same pathway can be targeted safely and effectively in patients. But the core result is already significant. It identifies a neuroimmune connection that had been largely overlooked in lung cancer, and it opens a fresh route for researchers trying to improve the odds that the immune system can recognize and contain the disease.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
